AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25711628 — intervention group
Group type: COMPARATOR
Intervention: Arthroscopic Bankart repair without ETAC (n = 44)
Number of subjects: 88
Study 24549145 — intervention group
Group type: EXPERIMENTAL
Intervention: CD4(+) T-cell ELISpot response at enrolment (n = 119)
Number of subjects: 366
Study 24549145 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline CD4(+) cell ELISpot responses (n = 119)
Number of subjects: 366
Study 24549145 — intervention group
Group type: EXPERIMENTAL
Intervention: CD8(+) T-cell immunity
Number of subjects: 366
Study 23936951 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human erythropoietin (rHuEPO) and aggressive intravenous iron therapy
Number of subjects: 100
Study 20825123 — intervention group
Group type: EXPERIMENTAL
Intervention: Constraint-Induced Movement Therapy (CIMT)
Number of subjects: 12
Study 20825123 — intervention group
Group type: COMPARATOR
Intervention: Bilateral treatment of equal intensity
Number of subjects: 12
Study 18158722 — intervention group
Group type: EXPERIMENTAL
Intervention: 9.7 microm particles
Number of subjects: 19
Study 18158722 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.6 microm particles
Number of subjects: 19
Study 18158722 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.1 microm particles
Number of subjects: 19
Study 16224652 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 40
Study 16224652 — intervention group
Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 40
Study 11953921 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary energy intake (DEI)
Number of subjects: 1397
Study 11953921 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary protein intake (DPI)
Number of subjects: 1397
Study 11953921 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum albumin
Number of subjects: 1397
Study 11953921 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatinine
Number of subjects: 1397
Study 11953921 — intervention group
Group type: EXPERIMENTAL
Intervention: Normalized protein catabolic rate (nPCR)
Number of subjects: 1397
Study 11953921 — intervention group
Group type: EXPERIMENTAL
Intervention: Equilibrated nPCR (enPCR)
Number of subjects: 1397
Study 11953921 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional status
Number of subjects: 1397
Study 11953921 — intervention group
Group type: EXPERIMENTAL
Intervention: Comorbidities
Number of subjects: 1397
Study 9646963 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 8666002 — intervention group
Group type: COMPARATOR
Intervention: 447C88 200 mg single dose
Number of subjects: 26
Study 8666002 — intervention group
Group type: COMPARATOR
Intervention: 447C88 800 mg single dose
Number of subjects: 26
Study 8666002 — intervention group
Group type: COMPARATOR
Intervention: 447C88 200 mg twice daily for 10 days
Number of subjects: 26
Study 8666002 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 2162255 — intervention group
Group type: EXPERIMENTAL
Intervention: KS1/4
Number of subjects: 11
Study 2162255 — intervention group
Group type: EXPERIMENTAL
Intervention: KS1/4-methotrexate
Number of subjects: 11
Study 374017 — intervention group
Group type: EXPERIMENTAL
Intervention: Sisomicin
Number of subjects: 38
Study 374017 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 31995557 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal progesterone (200mg daily self-administered suppository)
Number of subjects: 140
Study 31995557 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study 30784480 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined stress (G2): nutritional stress (30% less of maintenance diet) and heat stress (38–44 °C for 6 h/day)
Number of subjects: 16
Study 30784480 — intervention group
Group type: COMPARATOR
Intervention: Control (G1): maintenance diet under shed
Number of subjects: 16
Study 28794212 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiber meatballs plus wheat bread
Number of subjects: 40
Study 28794212 — intervention group
Group type: COMPARATOR
Intervention: Low-fiber meal (pork meatballs plus wheat bread)
Number of subjects: 40
Study 28794212 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiber bread with pork meatballs
Number of subjects: 40
Study 28794212 — intervention group
Group type: EXPERIMENTAL
Intervention: Vegetable patties with natural fiber content plus wheat bread
Number of subjects: 40
Study 26151178 — intervention group
Group type: EXPERIMENTAL
Intervention: Loading dose of 50,000 IU VTD3, followed by 25,000 IU at Week 4 and Week 8
Number of subjects: 150
Study 26151178 — intervention group
Group type: EXPERIMENTAL
Intervention: Loading dose of 100,000 IU VTD3, followed by 50,000 IU at Week 4 and Week 8
Number of subjects: 150
Study 26151178 — intervention group
Group type: EXPERIMENTAL
Intervention: Loading dose of 200,000 IU VTD3, followed by 100,000 IU at Week 4 and Week 8
Number of subjects: 150
Study 23841960 — intervention group
Group type: EXPERIMENTAL
Intervention: MUFA-meal (high in oleic acid)
Number of subjects: 20
Study 23841960 — intervention group
Group type: COMPARATOR
Intervention: SFA-meal (high in palmitic acid)
Number of subjects: 20
Study 21453832 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg (TNT trial)
Number of subjects: 11840
Study 21453832 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin 10 mg (TNT trial)
Number of subjects: 11840
Study 21453832 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg/day (IDEAL trial)
Number of subjects: 11840
Study 21453832 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin 20 mg/day (IDEAL trial)
Number of subjects: 11840
Study 21453832 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg/day (SPARCL trial)
Number of subjects: 11840
Study 21453832 — intervention group
Group type: COMPARATOR
Intervention: Placebo (SPARCL trial)
Number of subjects: 11840
Study 21453832 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with new-onset T2DM (across trials)
Number of subjects: 11840
Study 21453832 — intervention group
Group type: COMPARATOR
Intervention: Patients without new-onset T2DM (across trials)
Number of subjects: 11840
Study 19306955 — intervention group
Group type: EXPERIMENTAL
Intervention: Preterm formula
Number of subjects: 202
Study 19306955 — intervention group
Group type: COMPARATOR
Intervention: Banked breast milk
Number of subjects: 202
Study 19306955 — intervention group
Group type: COMPARATOR
Intervention: Term formula
Number of subjects: 202
Study 16705843 — intervention group
Group type: EXPERIMENTAL
Intervention: Wrist-ankle acupuncture
Number of subjects: 90
Study 16705843 — intervention group
Group type: EXPERIMENTAL
Intervention: Body acupuncture
Number of subjects: 90
Study 16705843 — intervention group
Group type: COMPARATOR
Intervention: Western routine medical treatment (control)
Number of subjects: 90
Study 11502699 — intervention group
Group type: EXPERIMENTAL
Intervention: Inherited bleeding tendency (hemophilia and von Willebrand disease)
Number of subjects: 76
Study 11502699 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 76
Study 11502699 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate to severe hemophilia
Number of subjects: 76
Study 9266448 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial carboplatin chemotherapy at a dose escalated to 1400 mg/hemisphere
Number of subjects: 21
Study 9266448 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial carboplatin chemotherapy
Number of subjects: 21
Study 8303595 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 40
Study 8303595 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 40
Study 2979674 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride 10 mg
Number of subjects: 6
Study 29497759 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based writing treatment
Number of subjects: 3
Study 29497759 — intervention group
Group type: EXPERIMENTAL
Intervention: Tau-U analysis
Number of subjects: 3
Study 28460255 — intervention group
Group type: EXPERIMENTAL
Intervention: Active transcutaneous vagus nerve stimulation (tVNS)
Number of subjects: 38
Study 28460255 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 38
Study 26630568 — intervention group
Group type: EXPERIMENTAL
Intervention: Salacia reticulata extract
Number of subjects: 0
Study 23520152 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-week Internet-based cognitive-behavioral prevention program for AN
Number of subjects: 36
Study 21496516 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT) bibliotherapy, Japanese translation of a self-help book, duration: 2 months reading period followed by a 2-month follow-up.
Number of subjects: 70
Study 21496516 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group (received no intervention initially).
Number of subjects: 70
Study 18299062 — intervention group
Group type: EXPERIMENTAL
Intervention: Wavefront-guided LASIK
Number of subjects: 27
Study 18299062 — intervention group
Group type: COMPARATOR
Intervention: Wavefront-optimized LASIK
Number of subjects: 27
Study 17196044 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine (TCM)‐style acupuncture with manual stimulation for depression
Number of subjects: 151
Study 17196044 — intervention group
Group type: COMPARATOR
Intervention: Nonspecific intervention using legitimate acupuncture points not specifically targeted to depressive symptoms
Number of subjects: 151
Study 17196044 — intervention group
Group type: COMPARATOR
Intervention: Waitlist condition (no intervention for 8 weeks)
Number of subjects: 151
Study 12499712 — intervention group
Group type: EXPERIMENTAL
Intervention: Mianserin 60 mg/day
Number of subjects: 100
Study 12499712 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 10693157 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (0.3 mg/kg i.v.)
Number of subjects: 18
Study 10693157 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 9322465 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal fentanyl 25 micrograms (Group S)
Number of subjects: 105
Study 9322465 — intervention group
Group type: EXPERIMENTAL
Intervention: Extradural fentanyl 50 micrograms with bupivacaine (Group E)
Number of subjects: 105
Study 9322465 — intervention group
Group type: COMPARATOR
Intervention: Extradural bupivacaine only (Group C)
Number of subjects: 105
Study 8478304 — intervention group
Group type: EXPERIMENTAL
Intervention: Dirithromycin 500 mg once daily
Number of subjects: 802
Study 8478304 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin 250 mg four times daily
Number of subjects: 802
Study 3523664 — intervention group
Group type: EXPERIMENTAL
Intervention: Enprofylline (14.1 mg/kg/day)
Number of subjects: 15
Study 3523664 — intervention group
Group type: COMPARATOR
Intervention: Theophylline (16.2 mg/kg/day)
Number of subjects: 15
Study 31567764 — intervention group
Group type: EXPERIMENTAL
Intervention: Butorphanol 0.1 mg (group I)
Number of subjects: 120
Study 31567764 — intervention group
Group type: EXPERIMENTAL
Intervention: Butorphanol 1 mg (group II)
Number of subjects: 120
Study 31567764 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (group III)
Number of subjects: 120
Study 28671104 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin
Number of subjects: 43
Study 28671104 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined reversed temporal muscle flap and random forehead flap technique
Number of subjects: 43
Study 25907982 — intervention group
Group type: EXPERIMENTAL
Intervention: Medial percutaneous hemi‐epiphysiodesis
Number of subjects: 9
Study 25907982 — intervention group
Group type: COMPARATOR
Intervention: Control group (no hemi‐epiphysiodesis)
Number of subjects: 9
Study 24099352 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine lozenge
Number of subjects: 54
Study 24099352 — intervention group
Group type: COMPARATOR
Intervention: Placebo lozenge
Number of subjects: 54
Study 21948348 — intervention group
Group type: EXPERIMENTAL
Intervention: CAMS care
Number of subjects: 32
Study 21948348 — intervention group
Group type: COMPARATOR
Intervention: Enhanced Care as Usual (E‐CAU)
Number of subjects: 32
Study 19688316 — intervention group
Group type: EXPERIMENTAL
Intervention: Qiyu oil gauze (QYOG)
Number of subjects: 60
Study 19688316 — intervention group
Group type: COMPARATOR
Intervention: Vaseline gauze (Control)
Number of subjects: 60
Study 18332644 — intervention group
Group type: EXPERIMENTAL
Intervention: SSRIs treatment
Number of subjects: 0
Study 18332644 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 15550364 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine
Number of subjects: 34
Study 15550364 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzydamine
Number of subjects: 34
Study 15550364 — intervention group
Group type: EXPERIMENTAL
Intervention: Both agents
Number of subjects: 34
Study 11152373 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 24
Study 11152373 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol
Number of subjects: 24
Study 9593078 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin, 40 mg once daily
Number of subjects: 10
Study 9593078 — intervention group
Group type: COMPARATOR
Intervention: Pravastatin, 40 mg once daily
Number of subjects: 10
Study 7640154 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal administration of 1.0 mg clonazepam
Number of subjects: 7
Study 7640154 — intervention group
Group type: EXPERIMENTAL
Intervention: Buccal administration of 1.0 mg clonazepam
Number of subjects: 7
Study 7640154 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous administration of 0.5 mg clonazepam
Number of subjects: 7
Study 2663163 — intervention group
Group type: EXPERIMENTAL
Intervention: guaimesal (500 mg, three times daily for seven days)
Number of subjects: 140
Study 2663163 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 140
Study 1096902 — intervention group
Group type: COMPARATOR
Intervention: Naproxen
Number of subjects: 100
Study 1096902 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin
Number of subjects: 100
Study 31370275 — intervention group
Group type: EXPERIMENTAL
Intervention: Two 45 min nutrition lessons using food models
Number of subjects: 203
Study 28923239 — intervention group
Group type: EXPERIMENTAL
Intervention: PA101 (40 mg)
Number of subjects: 24
Study 28923239 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 25316328 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol
Number of subjects: 172
Study 25316328 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 172
Study 25316328 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol with NAC administration
Number of subjects: 172
Study 24090377 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphate binder (PB) adherence
Number of subjects: 502
Study 24090377 — intervention group
Group type: COMPARATOR
Intervention: Cerebrovascular disease
Number of subjects: 502
Study 24090377 — intervention group
Group type: COMPARATOR
Intervention: Higher PTH levels
Number of subjects: 502
Study 24090377 — intervention group
Group type: COMPARATOR
Intervention: Lack of comprehension of appropriate PB use timing
Number of subjects: 502
Study 24090377 — intervention group
Group type: COMPARATOR
Intervention: Stopping PB after feeling better
Number of subjects: 502
Study 24090377 — intervention group
Group type: COMPARATOR
Intervention: Stopping PB after feeling worse
Number of subjects: 502
Study 24090377 — intervention group
Group type: COMPARATOR
Intervention: Years on dialysis
Number of subjects: 502
Study 24090377 — intervention group
Group type: COMPARATOR
Intervention: Serum phosphorus above 5.5 mg/dL
Number of subjects: 502
Study 24090377 — intervention group
Group type: COMPARATOR
Intervention: Encouragement by dialysis staff to be independent
Number of subjects: 502
Study 24090377 — intervention group
Group type: COMPARATOR
Intervention: Nephrologist explained PB use
Number of subjects: 502
Study 21884146 — intervention group
Group type: EXPERIMENTAL
Intervention: Penthrox inhaler sedation
Number of subjects: 20
Study 21884146 — intervention group
Group type: COMPARATOR
Intervention: Nitrous oxide sedation
Number of subjects: 20
Study 21884146 — intervention group
Group type: COMPARATOR
Intervention: Both sedation techniques
Number of subjects: 20
Study 18803554 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg rhTSH
Number of subjects: 28
Study 18803554 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.005 mg rhTSH
Number of subjects: 28
Study 18803554 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 17134956 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin therapy (10mg daily) with a low-fat diet
Number of subjects: 71
Study 17134956 — intervention group
Group type: COMPARATOR
Intervention: Low-fat diet only
Number of subjects: 71
Study 14872456 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training (experimental group [EG])
Number of subjects: 70
Study 14872456 — intervention group
Group type: COMPARATOR
Intervention: Range-of-motion exercises (control group [CG])
Number of subjects: 70
Study 11692298 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal zinc gluconate
Number of subjects: 91
Study 11692298 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study 9152291 — intervention group
Group type: EXPERIMENTAL
Intervention: Manganese-superoxide dismutase (Mn-SOD) activities in peripheral blood mononuclear cells
Number of subjects: 12
Study 9152291 — intervention group
Group type: EXPERIMENTAL
Intervention: Mn-SOD messenger RNA expression
Number of subjects: 12
Study 9152291 — intervention group
Group type: COMPARATOR
Intervention: Transcriptional activation of Mn-SOD gene in glomerular endothelial cells exposed to 5% serum
Number of subjects: 12
Study 7525233 — intervention group
Group type: EXPERIMENTAL
Intervention: Memorization of spatial location
Number of subjects: 0
Study 7525233 — intervention group
Group type: COMPARATOR
Intervention: Pressing a button for target location
Number of subjects: 0
Study 7525233 — intervention group
Group type: COMPARATOR
Intervention: Counting stimuli in target location
Number of subjects: 0
Study 7525233 — intervention group
Group type: COMPARATOR
Intervention: Passive viewing
Number of subjects: 0
Study 3046813 — intervention group
Group type: EXPERIMENTAL
Intervention: Postural manipulation to maximize QH (phase 2)
Number of subjects: 0
Study 3046813 — intervention group
Group type: COMPARATOR
Intervention: Postural manipulation to minimize QH (phase 1)
Number of subjects: 0
Study 31078831 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic supplements (Winclove's Ecologic® Barrier), consumed daily over eight weeks
Number of subjects: 71
Study 31078831 — intervention group
Group type: COMPARATOR
Intervention: Placebo, consumed daily over eight weeks
Number of subjects: 71
Study 31078831 — intervention group
Group type: COMPARATOR
Intervention: Non-depressed group (n = 20)
Number of subjects: 71
Study 28692905 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright light treatment
Number of subjects: 78
Study 28692905 — intervention group
Group type: COMPARATOR
Intervention: Control dim-red light
Number of subjects: 78
Study 25052347 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal calprotectin (FC) monitoring after stopping TNFα-blocking therapy
Number of subjects: 49
Study 25052347 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal fecal calprotectin concentrations during follow-up
Number of subjects: 49
Study 24059585 — intervention group
Group type: EXPERIMENTAL
Intervention: Follicular phase (low ALLO)
Number of subjects: 84
Study 24059585 — intervention group
Group type: EXPERIMENTAL
Intervention: Luteal phase (high ALLO)
Number of subjects: 84
Study 24059585 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall smoking cessation outcomes in L phase
Number of subjects: 84
Study 24059585 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall smoking cessation outcomes in F phase
Number of subjects: 84
Study 20236148 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Mesorectal Excision (TME)
Number of subjects: 124
Study 20236148 — intervention group
Group type: COMPARATOR
Intervention: Non-TME procedure
Number of subjects: 124
Study 20236148 — intervention group
Group type: EXPERIMENTAL
Intervention: TME with radiosensitizing chemotherapy
Number of subjects: 124
Study 20236148 — intervention group
Group type: COMPARATOR
Intervention: Non-TME with intra-operative radiotherapy
Number of subjects: 124
Study 20236148 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (TME and non-TME)
Number of subjects: 124
Study 18971535 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan
Number of subjects: 0
Study 18971535 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 0
Study 18971535 — intervention group
Group type: COMPARATOR
Intervention: Control of SBP < 140 mmHg
Number of subjects: 0
Study 18971535 — intervention group
Group type: COMPARATOR
Intervention: Control of SBP > 150 mmHg
Number of subjects: 0
Study 18971535 — intervention group
Group type: COMPARATOR
Intervention: Control of DBP > 85 mmHg
Number of subjects: 0
Study 17377092 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser-assisted drug delivery at 2.0 J/cm2
Number of subjects: 0
Study 17377092 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser-assisted drug delivery at 3.5 J/cm2
Number of subjects: 0
Study 14742768 — intervention group
Group type: EXPERIMENTAL
Intervention: β-blockers as secondary prevention of MI
Number of subjects: 0
Study 14742768 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose β-blockers with slow titration
Number of subjects: 0
Study 14742768 — intervention group
Group type: EXPERIMENTAL
Intervention: β-blockers in post-MI diabetic patients
Number of subjects: 0
Study 14742768 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower oral starting doses of β-blockers
Number of subjects: 0
Study 14742768 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardioselective β-blockers and albuterol
Number of subjects: 0
Study 14742768 — intervention group
Group type: EXPERIMENTAL
Intervention: β-blockers in patients with peripheral arterial disease
Number of subjects: 0
Study 11299089 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy diet (MDQI score)
Number of subjects: 964
Study 11299089 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor diet (MDQI score)
Number of subjects: 964
Study 11299089 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking status
Number of subjects: 964